CN108310450A - A kind of the medical haemostatic material and application process of quick injection film forming - Google Patents
A kind of the medical haemostatic material and application process of quick injection film forming Download PDFInfo
- Publication number
- CN108310450A CN108310450A CN201810384388.8A CN201810384388A CN108310450A CN 108310450 A CN108310450 A CN 108310450A CN 201810384388 A CN201810384388 A CN 201810384388A CN 108310450 A CN108310450 A CN 108310450A
- Authority
- CN
- China
- Prior art keywords
- liquid
- weight
- parts
- film forming
- haemostatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000463 material Substances 0.000 title claims abstract description 94
- 230000000025 haemostatic effect Effects 0.000 title claims abstract description 79
- 229940030225 antihemorrhagics Drugs 0.000 title claims abstract description 77
- 238000000034 method Methods 0.000 title claims abstract description 32
- 238000002347 injection Methods 0.000 title claims abstract description 21
- 239000007924 injection Substances 0.000 title claims abstract description 21
- 239000007788 liquid Substances 0.000 claims abstract description 114
- 230000023597 hemostasis Effects 0.000 claims abstract description 52
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 39
- 108010010803 Gelatin Proteins 0.000 claims abstract description 38
- 239000008273 gelatin Substances 0.000 claims abstract description 38
- 229920000159 gelatin Polymers 0.000 claims abstract description 38
- 235000019322 gelatine Nutrition 0.000 claims abstract description 38
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 38
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229910021389 graphene Inorganic materials 0.000 claims abstract description 32
- 239000012528 membrane Substances 0.000 claims abstract description 32
- 239000000843 powder Substances 0.000 claims abstract description 32
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 30
- 229920001661 Chitosan Polymers 0.000 claims abstract description 23
- 239000011806 microball Substances 0.000 claims abstract description 20
- 230000006835 compression Effects 0.000 claims abstract description 15
- 238000007906 compression Methods 0.000 claims abstract description 15
- 239000004310 lactic acid Substances 0.000 claims abstract description 15
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 15
- 229920000126 latex Polymers 0.000 claims abstract description 15
- 239000000839 emulsion Substances 0.000 claims abstract description 14
- 229920000058 polyacrylate Polymers 0.000 claims abstract description 14
- 235000010443 alginic acid Nutrition 0.000 claims abstract description 12
- 229920000615 alginic acid Polymers 0.000 claims abstract description 12
- 150000004781 alginic acids Chemical class 0.000 claims abstract description 12
- 239000000783 alginic acid Substances 0.000 claims abstract 2
- 229960001126 alginic acid Drugs 0.000 claims abstract 2
- 210000004369 blood Anatomy 0.000 claims description 35
- 239000008280 blood Substances 0.000 claims description 35
- 239000002245 particle Substances 0.000 claims description 30
- 229920001971 elastomer Polymers 0.000 claims description 28
- 238000002360 preparation method Methods 0.000 claims description 25
- 244000043261 Hevea brasiliensis Species 0.000 claims description 20
- 229920003052 natural elastomer Polymers 0.000 claims description 20
- 229920001194 natural rubber Polymers 0.000 claims description 20
- 239000000377 silicon dioxide Substances 0.000 claims description 17
- -1 graphite alkene Chemical class 0.000 claims description 16
- 239000007787 solid Substances 0.000 claims description 16
- 239000006210 lotion Substances 0.000 claims description 11
- 239000004215 Carbon black (E152) Substances 0.000 claims description 10
- 239000004743 Polypropylene Substances 0.000 claims description 10
- 229930195733 hydrocarbon Natural products 0.000 claims description 10
- 150000002430 hydrocarbons Chemical class 0.000 claims description 10
- 229920001155 polypropylene Polymers 0.000 claims description 10
- 235000013618 yogurt Nutrition 0.000 claims description 10
- 238000001179 sorption measurement Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 7
- 241000790917 Dioxys <bee> Species 0.000 claims description 6
- 229910003978 SiClx Inorganic materials 0.000 claims description 6
- 239000010410 layer Substances 0.000 claims description 6
- 210000000988 bone and bone Anatomy 0.000 claims description 5
- 229910002804 graphite Inorganic materials 0.000 claims description 5
- 239000010439 graphite Substances 0.000 claims description 5
- 210000002435 tendon Anatomy 0.000 claims description 5
- 239000002356 single layer Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000003292 glue Substances 0.000 claims description 3
- 150000001336 alkenes Chemical class 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 239000004816 latex Substances 0.000 claims 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims 1
- 206010052428 Wound Diseases 0.000 abstract description 49
- 208000027418 Wounds and injury Diseases 0.000 abstract description 49
- 230000002439 hemostatic effect Effects 0.000 abstract description 41
- 208000014674 injury Diseases 0.000 abstract description 10
- 230000008733 trauma Effects 0.000 abstract description 10
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 229910002012 Aerosil® Inorganic materials 0.000 abstract description 3
- 230000035876 healing Effects 0.000 abstract description 2
- 230000000157 blood function Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 description 15
- 230000023555 blood coagulation Effects 0.000 description 15
- 241000283973 Oryctolagus cuniculus Species 0.000 description 14
- 208000032843 Hemorrhage Diseases 0.000 description 12
- 208000034158 bleeding Diseases 0.000 description 12
- 230000000740 bleeding effect Effects 0.000 description 12
- 210000005069 ears Anatomy 0.000 description 7
- 238000011587 new zealand white rabbit Methods 0.000 description 7
- 238000010998 test method Methods 0.000 description 7
- 230000029663 wound healing Effects 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- RYDFXSRVZBYYJV-TYYBGVCCSA-N (e)-but-2-enedioic acid;sodium Chemical compound [Na].OC(=O)\C=C\C(O)=O RYDFXSRVZBYYJV-TYYBGVCCSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 235000008291 Poterium sanguisorba Nutrition 0.000 description 1
- 244000173853 Sanguisorba officinalis Species 0.000 description 1
- 235000008282 Sanguisorba officinalis Nutrition 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 239000004965 Silica aerogel Substances 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000011162 core material Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 239000003752 hydrotrope Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- UGTZMIPZNRIWHX-UHFFFAOYSA-K sodium trimetaphosphate Chemical compound [Na+].[Na+].[Na+].[O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 UGTZMIPZNRIWHX-UHFFFAOYSA-K 0.000 description 1
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0026—Sprayable compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0036—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/02—Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/06—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/08—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/104—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
The present invention provides a kind of the medical haemostatic materials and application process of quick injection film forming.The obtained A liquid that is uniformly dispersed is added in nature rubber latex in aerosil powder, chitosan microball, graphene and gelatin corpuscle, lactic acid, alginic acid, polyacrylate emulsion are uniformly dispersed to form B liquid, up to the medical haemostatic material for the quick injection film forming being made of A liquid and B liquid, A, B liquid are sprayed into mixing simultaneously when use, haemostatic membrane is formed in wound, achievees the purpose that quick-acting haemostatic powder.The hemostatic material of this method is by quickly forming the haemostatic membrane with strong adherence hemostasis by compression, and the material with absorption blood function, haemostatic membrane can be made to be fitted closely with wound, achieve the purpose that quick-acting haemostatic powder, reduce wound trauma, not only stops blooding excellent, and the healing of wound can be effectively facilitated, with good biocompatibility, and need not individually wrap up, it is easy to use, be first aid, household indispensable material.
Description
Technical field
The present invention relates to medical material fields, and in particular to the preparation and application of medical haemostatic material, more particularly to one
Kind medical haemostatic material and application process that quickly injection forms a film.
Background technology
Haemophilia is not only second main cause dead in wounded patient, and it is to cause blood coagulation to bleed profusely with wound
The Major Risk Factors of obstacle, bleeding late also play an important role in morbidity and mortality, continue low blood pressure, sepsis
Disease, a large amount of red blood cells and plasma products seepage flow can lead to a variety of organ failures.Therefore for surgeon, hemostasis is clinical
Important challenge in work realizes that quick-acting haemostatic powder direct result is to improve hemodynamic stability and avoid the potential of blood transfusion
Negative effect.
Earliest, hemostasis is mainly using wrapping, but haemostatic effect is poor, with the development of science and technology, gradually occur with
The hemostatic material for wrapping up cooperation, becomes the main path of hemostasis.Therefore the non-absorbability topical hemostatic agent such as bone wax is largely answered
For clinic, and it is applied to surgical operation always for quite a long time and stops blooding, but since this kind of hemostatic material histocompatbility is poor,
Easily cause foreign body reaction, it is difficult to degrade, cause the infection of art area and other complication inevitable.Novel hemostatic material, it is such as fine
Element, chitin, polyvinyl alcohol, collagen, chitosan etc. are tieed up, has obtained preferable application in terms of hemostasis.
Chinese invention patent application number 201110442310.5 discloses a kind of high-efficiency silicon oxide hemostasis material, hemostatic material
Material is that silica has adsorbed a large amount of calcium ion, and the adsorption activation material of blood plasma；The invention reaction condition is mild, grasps
Make simple and easy to do, raw material is cheap and easy to get；Obtained hemostatic material product haemostatic effect is fabulous, is used as and is stopped by using silica
Blood material can significantly improve the biocompatibility of hemostatic material, present applying in vivo for silica hemostatic material
Good prospect；The distinctive porous of Metaporous silicon dioxide material can contribute to controlling for wound with adsorption antibacterial element and anodyne etc.
It treats, the material of the invention can be used for the hemostasis of different medical applications, combine, can be made into other medical materials, medical instrument
Adhesive bandage, infusion paste, adhesive dressing, tablet and capsule core material, operation packet, first-aid dressing etc..
Chinese invention patent application number 201410748904.2 discloses a kind of absorbable hemostasia membrane material, main component
Including starch, carboxymethyl cellulose, gelatin, the weight ratio of starch, carboxymethyl cellulose and gelatin is（1~4）:（1~2）:（1~
3）；The invention also discloses a kind of preparation method of absorbable hemostasia membrane material, by preparation by way of blended under agitation
Starch solution, cmc soln, gelatin solution are uniformly mixed, and membrane material is made；Hemostasis membrane material prepared by the invention
With good biocompatibility, absorbable and degradable, hemostasis while, has effects that prevent adhesion again.In addition, the invention system
Compound hemostatic material raw material sources it is extensive, safe and non-toxic, preparation process is simple.
Chinese invention patent application number 201610110213.9 discloses a kind of complex polysaccharide hemostasis film and its preparation side
Method, component and each component mass fraction are as follows：10 ~ 20 parts of chitosan, 2 ~ 8 parts of glucose, 3 ~ 6 parts of methylcellulose, gelatin 1 ~ 5
Part, 4 ~ 7 parts of pectin, 4 ~ 7 parts of sodium trimetaphosphate, 8 ~ 20 parts of polyalcohol, 5 ~ 8 parts of agar, 2 ~ 8 parts of sorbic acid, sodium alginate 5 ~ 10
Part, 3 ~ 6 parts of Radix Notoginseng, 1 ~ 3 part of fumaric acid sodium, 2 ~ 5 parts of garden burnet.The invention polysaccharide is that matrix is added hemostatic compositions appropriate and helped
Agent prepares film-like hemostatic material, and compared with conventional pulvis or spray, membranaceous hemostatic material can synchronize in terms of two to be stopped
Blood, bleeding early stage, membrane body are similar to tourniquet, can quick-acting haemostatic powder, while hemostatic compositions in film synchronize hemostasis, double-hemostasis function work(
Can, the bleeding time is substantially reduced, haemostatic effect is apparent, and easy to use.
Chinese invention patent application number 201610574391.7 discloses a kind of medical hemostatic closed material and composition, and one
Kind medical toughness closes hemostatic material, by with one of A-R-A or B-R1-B structures polymerization or be condensed or two kinds
The mixture of substances of structure is condensed or is polymerized.The medical toughness closing hemostatic material and composition of the present invention, by connecing branch
The reactive group that polymerization or condensation reaction interconnect can occur, form film forming or the material with liquid absorption capacity, make
Used time, can be administered position will form a film or water-absorbent material by energy-rich bond it is compound by form high tenacity membrane material or water-absorption material
Material, to achieve the effect that preferably to close wound or hemostasis, prevents occult blood or secondary bleeding possibility.
According to above-mentioned, the hemostatic material in existing scheme mainly achievees the purpose that hemostasis using quick adsorption blood, by
It is influenced by blood pressure in wounds streamed blood, typically injection is bled, and acute bleeding excess can be caused by depending merely on absorption blood, or even jeopardize life
Life, thus assist finger-press method, pressure dressing, cushioning song limb method and hemostasis with tourniquet etc., however hemostasis by compression require compared with
Height, wrapping is extremely inconvenient, and wrapping, which kicks the beam, is difficult to achieve the purpose that hemostasis, and wrapping is overweight to cause secondary damage.
Invention content
For current the problem of being difficult to effectively stop blooding using wider quick adsorption hemostatic material, and it is aided with hemostasis by compression
When exist require it is high, it is difficult to effective hemostasis by compression, the defects of wrapping hemostasis is difficult to operate, easily cause secondary damage, the present invention carries
Go out a kind of the medical haemostatic material and application process of quick injection film forming, to effectively realize quick-acting haemostatic powder, and the side of wrapping
Just, safety is good.
Specific technical solution of the present invention is as follows：
A kind of medical haemostatic material of quick injection film forming, the medical haemostatic material is by 53 ~ 58 parts by weight A liquid and 42 ~ 47 weights
Measure part B liquid composition；The preparation process of the A liquid is：8 ~ 12 parts by weight of silica airsetting rubber powders, 10 ~ 15 parts by weight shells are poly-
Sugared microballoon, 6 ~ 10 parts by weight of graphite alkene and 11 ~ 14 parts by weight gelatin corpuscles are added in 49 ~ 65 parts by weight of natural rubber lotions, surpass
Sound is uniformly dispersed, and A liquid is made；The preparation process of the B liquid is：20 ~ 25 parts by weight lactic acid, 8 ~ 14 parts by weight alginic acids are added
In 61 ~ 72 parts by weight of polypropylene yogurt liquid, ultrasonic disperse is uniform, and B liquid is made.
Preferably, the preparation process of the A liquid is：By 10 parts by weight of silica airsetting rubber powders, 13 parts by weight chitosans
Microballoon, 7 parts by weight of graphite alkene and 13 parts by weight gelatin corpuscles are added in 57 parts by weight of natural rubber lotions, and ultrasonic disperse is uniform,
A liquid is made.
Preferably, the grain diameter of the aerosil powder is 3 ~ 10 μm, and density is 0.06 ~ 0.12g/cm3, hole
Gap rate is 95 ~ 98%.
Preferably, the grain diameter of the chitosan microball is 5 ~ 20 μm, and porosity is 92 ~ 96%.
Preferably, the graphene is single-layer graphene, bilayer graphene, lacks in layer graphene or multi-layer graphene extremely
Few one kind, grain diameter are 10 ~ 20 μm, and specific surface area is 2000 ~ 2500m2/ g, porosity are 94 ~ 99%.
Preferably, the gelatin corpuscle is at least one in skin gelatin particle, bone gelatin particle or tendon gelatin corpuscle
Kind, grain diameter is 20 ~ 40 μm.
Preferably, the solid content of the nature rubber latex is 40 ~ 50%, and pH value is 6 ~ 7, rubber hydrocarbon in natural rubber
Content is 92 ~ 96%.
Preferably, the preparation process of the B liquid is：66 parts by weight are added in 23 parts by weight lactic acid, 11 parts by weight alginic acids
In polyacrylate emulsion, ultrasonic disperse is uniform, and B liquid is made.
Preferably, the solid content of the polyacrylate emulsion is 35 ~ 40%, and pH value is 6 ~ 7.
Nature rubber latex is a kind of high polymer aqua type colloidal dispersion of biosynthesis, to gather cis- 1.4 1 isoamyl two
Based on alkene, and there is the substance of ten several components.Its main component is rubber hydrocarbon, water, non-rubber substance, and wherein non-rubber substance is main
It is made of protein, lipides, the molten object of acetone, the hydrotrope, inorganic salts etc..For Heveatex because of its good film-forming property, gel strength is high,
Film can be rapidly solidificated by being reacted with lactic acid；Polyacrylate emulsion self-crosslinkable forms the film of reticular structure, and the present invention passes through upper
It states two kinds of films and collectively constitutes the haemostatic membrane with strong adherence hemostasis by compression, achieve the purpose that hemostasis.Silica airsetting simultaneously
Glue, chitosan microball, graphene are the particle of high porosity, have strong adsorption ability, can quick adsorption outflow blood,
Achieve the purpose that efficiently to stop blooding jointly with haemostatic membrane.
A kind of application process of the medical haemostatic material of quick injection film forming, the specific method is as follows：
53 ~ 58 parts by weight A liquid, 42 ~ 47 parts by weight B liquid are respectively charged into two independent spaces of same container bottle setting, are made
Used time is sprayed using pressing, and A liquid, B liquid are ejected in wound simultaneously to be mixed, and nature rubber latex is rapidly solidificated into after meeting lactic acid
Film collectively constitutes the haemostatic membrane with strong adherence hemostasis by compression, silica airsetting therein with polyacrylate emulsion film forming
The blood that glue, chitosan microball, graphene quick adsorption flow out reaches fast short stopping to make haemostatic membrane be fitted closely with wound
Blood, the purpose for reducing wound trauma.
The present invention provides a kind of the medical haemostatic materials and application process of quick injection film forming, compared with prior art,
Its feature protruded and excellent effect are：
1, it proposes quickly form haemostatic membrane and adsorbs medical haemostatic material and application process that the quick injection of blood forms a film.
2, it is rapidly solidificated into film after meeting lactic acid by nature rubber latex, being collectively constituted with polyacrylate emulsion film forming has
The haemostatic membrane of strong adherence hemostasis by compression achievees the purpose that effectively to stop blooding.
3, by the blood that aerosil, chitosan microball, graphene quick adsorption flow out in hemostatic material, make
It obtains haemostatic membrane to fit closely with wound, achievees the purpose that quick-acting haemostatic powder, reduces wound trauma, not only stop blooding excellent, and can
The healing of wound is effectively facilitated, there is good biocompatibility.
4, hemostatic material produced by the present invention need not be wrapped up individually, easy to use, be first aid, household indispensable material.
Specific implementation mode
In the following, the present invention will be further described in detail by way of specific embodiments, but this should not be interpreted as to the present invention
Range be only limitted to example below.Without departing from the idea of the above method of the present invention, according to ordinary skill
The various replacements or change that knowledge and customary means are made, should be included in the scope of the present invention.
Embodiment 1
Hemostatic material group becomes：
Medical haemostatic material is made of A liquid and B liquid.
The preparation process of A liquid is：By 10 parts by weight of silica airsetting rubber powders, 13 parts by weight chitosan microballs, 7 parts by weight
Graphene and 13 parts by weight gelatin corpuscles are added in 57 parts by weight of natural rubber lotions, and ultrasonic disperse is uniform, and A liquid is made；Dioxy
The average particle size of SiClx airsetting rubber powder is 6 μm, density 0.09g/cm3, porosity 95%；Chitosan microball is averaged
Grain diameter is 12 μm, porosity 94%；Graphene is single-layer graphene, and average particle size is 14 μm, and specific surface area is
2200m2/ g, porosity 95%；Gelatin corpuscle is skin gelatin particle, and average particle size is 32 μm；Nature rubber latex
Solid content is 46%, pH value 6.5, and the content of rubber hydrocarbon is 94% in natural rubber.
The preparation process of B liquid is：66 parts by weight of polypropylene yogurt liquid are added in 23 parts by weight lactic acid, 11 parts by weight alginic acids
In, ultrasonic disperse is uniform, and B liquid is made；The solid content of polyacrylate emulsion is 37%, pH value 6.5.
Application process is：
56 parts by weight A liquid, 44 parts by weight B liquid are respectively charged into two independent spaces of same container bottle setting, when use adopts
It is sprayed with pressing, A liquid, B liquid are ejected in wound simultaneously to be mixed, and the hemostasis with strong adherence hemostasis by compression is quickly formed
Film achievees the purpose that quick-acting haemostatic powder, reduces wound trauma.
Test method：
Hemostatic material made from embodiment 1 is sprayed on clean breadboard, haemostatic membrane is formed, records film formation time；With No. 8 needles
Head punctures rabbit ears, draws the rabbit venous blood of 4mL, and venous blood fresh 0.5mL is coated in hemostasis film surface,
Film is tilted 45 degree after 1min, until drop of blood does not flow, records whole blood clotting time；
It is cut out on new zealand white rabbit using scalpel（1×1）cm2Ear's phleborrhagia surface of a wound and（1×1）cm2Ear
Hemostatic material made from embodiment 1 is sprayed at wound surface by the arterial hamorrhage surface of a wound, measures the bleeding stopping period of haemostatic membrane, observation
Wound healing situation.
Film formation time, whole blood clotting time and the hemostasis of the medical haemostatic material of the embodiment 1 measured by the above method
Time is as shown in table 1.
Embodiment 2
Hemostatic material group becomes：
Medical haemostatic material is made of A liquid and B liquid.
The preparation process of A liquid is：By 8 parts by weight of silica airsetting rubber powders, 10 parts by weight chitosan microballs, 6 parts by weight
Graphene and 11 parts by weight gelatin corpuscles are added in 65 parts by weight of natural rubber lotions, and ultrasonic disperse is uniform, and A liquid is made；Dioxy
The average particle size of SiClx airsetting rubber powder is 4 μm, density 0.06g/cm3, porosity 95%；Chitosan microball is averaged
Grain diameter is 5 μm, porosity 92%；Graphene is bilayer graphene, and average particle size is 10 μm, and specific surface area is
2000m2/ g, porosity 94%；Gelatin corpuscle is bone gelatin particle, and average particle size is 20 μm；Nature rubber latex is consolidated
Content is 40%, pH value 6, and the content of rubber hydrocarbon is 92% in natural rubber.
The preparation process of B liquid is：72 parts by weight of polypropylene yogurt liquid are added in 20 parts by weight lactic acid, 8 parts by weight alginic acids
In, ultrasonic disperse is uniform, and B liquid is made；The solid content of polyacrylate emulsion is 35%, pH value 6.
Application process is：
53 parts by weight A liquid, 47 parts by weight B liquid are respectively charged into two independent spaces of same container bottle setting, when use adopts
It is sprayed with pressing, A liquid, B liquid are ejected in wound simultaneously to be mixed, and the hemostasis with strong adherence hemostasis by compression is quickly formed
Film achievees the purpose that quick-acting haemostatic powder, reduces wound trauma.
Test method：
Hemostatic material made from embodiment 2 is sprayed on clean breadboard, haemostatic membrane is formed, records film formation time；With No. 8 needles
Head punctures rabbit ears, draws the rabbit venous blood of 4mL, and venous blood fresh 0.5mL is coated in hemostasis film surface,
Film is tilted 45 degree after 1min, until drop of blood does not flow, records whole blood clotting time；
It is cut out on new zealand white rabbit using scalpel（1×1）cm2Ear's phleborrhagia surface of a wound and（1×1）cm2Ear
Hemostatic material made from embodiment 2 is sprayed at wound surface by the arterial hamorrhage surface of a wound, measures the bleeding stopping period of haemostatic membrane, observation
Wound healing situation.
Film formation time, whole blood clotting time and the hemostasis of the medical haemostatic material of the embodiment 2 measured by the above method
Time is as shown in table 1.
Embodiment 3
Hemostatic material group becomes：
Medical haemostatic material is made of A liquid and B liquid.
The preparation process of A liquid is：By 12 parts by weight of silica airsetting rubber powders, 15 parts by weight chitosan microballs, 10 weight
Part graphene and 14 parts by weight gelatin corpuscles are added in 49 parts by weight of natural rubber lotions, and ultrasonic disperse is uniform, and A liquid is made；Two
The average particle size of silica aerogel powder is 10 μm, density 0.12g/cm3, porosity 998%；Chitosan microball
Average particle size is 20 μm, porosity 96%；Graphene is few layer graphene, and average particle size is 20 μm, specific surface area
For 2500m2/ g, porosity 99%；Gelatin corpuscle is tendon gelatin corpuscle, and average particle size is 40 μm；Nature rubber latex
Solid content be 50%, pH value 7, the content of rubber hydrocarbon is 96% in natural rubber.
The preparation process of B liquid is：61 parts by weight of polypropylene yogurt liquid are added in 25 parts by weight lactic acid, 14 parts by weight alginic acids
In, ultrasonic disperse is uniform, and B liquid is made；The solid content of polyacrylate emulsion is 40%, pH value 7.
Application process is：
58 parts by weight A liquid, 42 parts by weight B liquid are respectively charged into two independent spaces of same container bottle setting, when use adopts
It is sprayed with pressing, A liquid, B liquid are ejected in wound simultaneously to be mixed, and the hemostasis with strong adherence hemostasis by compression is quickly formed
Film achievees the purpose that quick-acting haemostatic powder, reduces wound trauma.
Test method：
Hemostatic material made from embodiment 3 is sprayed on clean breadboard, haemostatic membrane is formed, records film formation time；With No. 8 needles
Head punctures rabbit ears, draws the rabbit venous blood of 4mL, and venous blood fresh 0.5mL is coated in hemostasis film surface,
Film is tilted 45 degree after 1min, until drop of blood does not flow, records whole blood clotting time；
It is cut out on new zealand white rabbit using scalpel（1×1）cm2Ear's phleborrhagia surface of a wound and（1×1）cm2Ear
Hemostatic material made from embodiment 3 is sprayed at wound surface by the arterial hamorrhage surface of a wound, measures the bleeding stopping period of haemostatic membrane, observation
Wound healing situation.
Film formation time, whole blood clotting time and the hemostasis of the medical haemostatic material of the embodiment 3 measured by the above method
Time is as shown in table 1.
Embodiment 4
Hemostatic material group becomes：
Medical haemostatic material is made of A liquid and B liquid.
The preparation process of A liquid is：By 9 parts by weight of silica airsetting rubber powders, 11 parts by weight chitosan microballs, 7 parts by weight
Graphene and 12 parts by weight gelatin corpuscles are added in 61 parts by weight of natural rubber lotions, and ultrasonic disperse is uniform, and A liquid is made；Dioxy
The average particle size of SiClx airsetting rubber powder is 5 μm, density 0.07g/cm3, porosity 96%；Chitosan microball is averaged
Grain diameter is 8 μm, porosity 93%；Graphene is multi-layer graphene, and average particle size is 13 μm, and specific surface area is
2400m2/ g, porosity 98%；Gelatin corpuscle is skin gelatin particle, and average particle size is 25 μm；Nature rubber latex
Solid content is 42%, pH value 6, and the content of rubber hydrocarbon is 93% in natural rubber.
The preparation process of B liquid is：68 parts by weight of polypropylene yogurt liquid are added in 22 parts by weight lactic acid, 10 parts by weight alginic acids
In, ultrasonic disperse is uniform, and B liquid is made；The solid content of polyacrylate emulsion is 36%, pH value 7.
Application process is：
55 parts by weight A liquid, 45 parts by weight B liquid are respectively charged into two independent spaces of same container bottle setting, when use adopts
It is sprayed with pressing, A liquid, B liquid are ejected in wound simultaneously to be mixed, and the hemostasis with strong adherence hemostasis by compression is quickly formed
Film achievees the purpose that quick-acting haemostatic powder, reduces wound trauma.
Test method：
Hemostatic material made from embodiment 4 is sprayed on clean breadboard, haemostatic membrane is formed, records film formation time；With No. 8 needles
Head punctures rabbit ears, draws the rabbit venous blood of 4mL, and venous blood fresh 0.5mL is coated in hemostasis film surface,
Film is tilted 45 degree after 1min, until drop of blood does not flow, records whole blood clotting time；
It is cut out on new zealand white rabbit using scalpel（1×1）cm2Ear's phleborrhagia surface of a wound and（1×1）cm2Ear
Hemostatic material made from embodiment 4 is sprayed at wound surface by the arterial hamorrhage surface of a wound, measures the bleeding stopping period of haemostatic membrane, observation
Wound healing situation.
Film formation time, whole blood clotting time and the hemostasis of the medical haemostatic material of the embodiment 4 measured by the above method
Time is as shown in table 1.
Embodiment 5
Hemostatic material group becomes：
Medical haemostatic material is made of A liquid and B liquid.
The preparation process of A liquid is：By 11 parts by weight of silica airsetting rubber powders, 14 parts by weight chitosan microballs, 9 parts by weight
Graphene and 13 parts by weight gelatin corpuscles are added in 53 parts by weight of natural rubber lotions, and ultrasonic disperse is uniform, and A liquid is made；Dioxy
The average particle size of SiClx airsetting rubber powder is 8 μm, density 0.1g/cm3, porosity 97%；Average of chitosan microball
Grain grain size is 15 μm, porosity 95%；Graphene is single-layer graphene, and average particle size is 17 μm, and specific surface area is
2100m2/ g, porosity 95%；Gelatin corpuscle is bone gelatin particle, and average particle size is 35 μm；Nature rubber latex is consolidated
Content is 48%, pH value 7, and the content of rubber hydrocarbon is 95% in natural rubber.
The preparation process of B liquid is：63 parts by weight of polypropylene yogurt liquid are added in 24 parts by weight lactic acid, 13 parts by weight alginic acids
In, ultrasonic disperse is uniform, and B liquid is made；The solid content of polyacrylate emulsion is 38%, pH value 7.
Application process is：
57 parts by weight A liquid, 43 parts by weight B liquid are respectively charged into two independent spaces of same container bottle setting, when use adopts
It is sprayed with pressing, A liquid, B liquid are ejected in wound simultaneously to be mixed, and the hemostasis with strong adherence hemostasis by compression is quickly formed
Film achievees the purpose that quick-acting haemostatic powder, reduces wound trauma.
Test method：
Hemostatic material made from embodiment 5 is sprayed on clean breadboard, haemostatic membrane is formed, records film formation time；With No. 8 needles
Head punctures rabbit ears, draws the rabbit venous blood of 4mL, and venous blood fresh 0.5mL is coated in hemostasis film surface,
Film is tilted 45 degree after 1min, until drop of blood does not flow, records whole blood clotting time；
It is cut out on new zealand white rabbit using scalpel（1×1）cm2Ear's phleborrhagia surface of a wound and（1×1）cm2Ear
Hemostatic material made from embodiment 5 is sprayed at wound surface by the arterial hamorrhage surface of a wound, measures the bleeding stopping period of haemostatic membrane, observation
Wound healing situation.
Film formation time, whole blood clotting time and the hemostasis of the medical haemostatic material of the embodiment 5 measured by the above method
Time is as shown in table 1.
Embodiment 6
Hemostatic material group becomes：
Medical haemostatic material is made of A liquid and B liquid.
The preparation process of A liquid is：By 10 parts by weight of silica airsetting rubber powders, 12 parts by weight chitosan microballs, 8 parts by weight
Graphene and 12 parts by weight gelatin corpuscles are added in 58 parts by weight of natural rubber lotions, and ultrasonic disperse is uniform, and A liquid is made；Dioxy
The average particle size of SiClx airsetting rubber powder is 6 μm, density 0.09g/cm3, porosity 96%；Chitosan microball is averaged
Grain diameter is 15 μm, porosity 94%；Graphene is bilayer graphene, and average particle size is 15 μm, and specific surface area is
2300m2/ g, porosity 96%；Gelatin corpuscle is tendon gelatin corpuscle, and average particle size is 30 μm；Nature rubber latex
Solid content is 45%, pH value 6.5, and the content of rubber hydrocarbon is 94% in natural rubber.
The preparation process of B liquid is：67 parts by weight of polypropylene yogurt liquid are added in 22 parts by weight lactic acid, 11 parts by weight alginic acids
In, ultrasonic disperse is uniform, and B liquid is made；The solid content of polyacrylate emulsion is 38%, pH value 6.5.
Application process is：
56 parts by weight A liquid, 44 parts by weight B liquid are respectively charged into two independent spaces of same container bottle setting, when use adopts
It is sprayed with pressing, A liquid, B liquid are ejected in wound simultaneously to be mixed, and the hemostasis with strong adherence hemostasis by compression is quickly formed
Film achievees the purpose that quick-acting haemostatic powder, reduces wound trauma.
Test method：
Hemostatic material made from embodiment 6 is sprayed on clean breadboard, haemostatic membrane is formed, records film formation time；With No. 8 needles
Head punctures rabbit ears, draws the rabbit venous blood of 4mL, and venous blood fresh 0.5mL is coated in hemostasis film surface,
Film is tilted 45 degree after 1min, until drop of blood does not flow, records whole blood clotting time；
It is cut out on new zealand white rabbit using scalpel（1×1）cm2Ear's phleborrhagia surface of a wound and（1×1）cm2Ear
Hemostatic material made from embodiment 6 is sprayed at wound surface by the arterial hamorrhage surface of a wound, measures the bleeding stopping period of haemostatic membrane, observation
Wound healing situation.
Film formation time, whole blood clotting time and the hemostasis of the medical haemostatic material of the embodiment 6 measured by the above method
Time is as shown in table 1.
Comparative example 1
Hemostatic material group becomes：
Medical haemostatic material is made of A liquid and B liquid.
The preparation process of A liquid is：12 parts by weight gelatin corpuscles are added in 88 parts by weight of natural rubber lotions, ultrasonic disperse
Uniformly, A liquid is made；Gelatin corpuscle is tendon gelatin corpuscle, and average particle size is 30 μm；The solid content of nature rubber latex is
45%, pH value 6.5, the content of rubber hydrocarbon is 94% in natural rubber.
The preparation process of B liquid is：11 parts by weight alginic acids are added in 67 parts by weight of polypropylene yogurt liquid, ultrasonic disperse is equal
It is even, B liquid is made；The solid content of polyacrylate emulsion is 38%, pH value 6.5.
Application process is：
56 parts by weight A liquid, 44 parts by weight B liquid are respectively charged into two independent spaces of same container bottle setting, when use adopts
It is sprayed with pressing, A liquid, B liquid are ejected in wound simultaneously to be mixed, and the hemostasis with strong adherence hemostasis by compression is quickly formed
Film achievees the purpose that quick-acting haemostatic powder, reduces wound trauma.
Test method：
Hemostatic material made from comparative example 1 is sprayed on clean breadboard, haemostatic membrane is formed, records film formation time；With No. 8 needles
Head punctures rabbit ears, draws the rabbit venous blood of 4mL, and venous blood fresh 0.5mL is coated in hemostasis film surface,
Film is tilted 45 degree after 1min, until drop of blood does not flow, records whole blood clotting time；
It is cut out on new zealand white rabbit using scalpel（1×1）cm2Ear's phleborrhagia surface of a wound and（1×1）cm2Ear
Hemostatic material made from comparative example 1 is sprayed at wound surface by the arterial hamorrhage surface of a wound, measures the bleeding stopping period of haemostatic membrane, observation
Wound healing situation.
Film formation time, whole blood clotting time and the hemostasis of the medical haemostatic material of the comparative example 1 measured by the above method
Time is as shown in table 1.
Table 1：
Claims (10)
1. a kind of medical haemostatic material of quick injection film forming, which is characterized in that the medical haemostatic material is by 53 ~ 58 parts by weight
A liquid and 42 ~ 47 parts by weight B liquid composition；The preparation process of the A liquid is：By 8 ~ 12 parts by weight of silica airsetting rubber powders, 10 ~
The natural rubber of 49 ~ 65 parts by weight is added in 15 parts by weight chitosan microballs, 6 ~ 10 parts by weight of graphite alkene and 11 ~ 14 parts by weight gelatin corpuscles
In latex solution, ultrasonic disperse is uniform, and A liquid is made；The preparation process of the B liquid is：By 20 ~ 25 parts by weight lactic acid, 8 ~ 14 weight
Part alginic acid is added in 61 ~ 72 parts by weight of polypropylene yogurt liquid, and ultrasonic disperse is uniform, and B liquid is made.
2. a kind of medical haemostatic material of quick injection film forming according to claim 1, which is characterized in that the system of the A liquid
It is for process：By 10 parts by weight of silica airsetting rubber powders, 13 parts by weight chitosan microballs, 7 parts by weight of graphite alkene and 13 weight
Part gelatin corpuscle is added in 57 parts by weight of natural rubber lotions, and ultrasonic disperse is uniform, and A liquid is made.
3. a kind of medical haemostatic material of quick injection film forming according to claim 1 or claim 2, which is characterized in that the dioxy
The grain diameter of SiClx airsetting rubber powder is 3 ~ 10 μm, and density is 0.06 ~ 0.12g/cm3, porosity is 95 ~ 98%.
4. a kind of medical haemostatic material of quick injection film forming according to claim 1 or claim 2, which is characterized in that the shell is poly-
The grain diameter of sugared microballoon is 5 ~ 20 μm, and porosity is 92 ~ 96%.
5. a kind of medical haemostatic material of quick injection film forming according to claim 1 or claim 2, which is characterized in that the graphite
Alkene is single-layer graphene, bilayer graphene, few at least one of layer graphene or multi-layer graphene, and grain diameter is 10 ~ 20 μ
M, specific surface area are 2000 ~ 2500m2/ g, porosity are 94 ~ 99%.
6. a kind of medical haemostatic material of quick injection film forming according to claim 1 or claim 2, which is characterized in that the gelatin
Particle is at least one of skin gelatin particle, bone gelatin particle or tendon gelatin corpuscle, and grain diameter is 20 ~ 40 μm.
7. a kind of medical haemostatic material of quick injection film forming according to claim 1 or claim 2, which is characterized in that described natural
The solid content of rubber latex is 40 ~ 50%, and pH value is 6 ~ 7, and the content of rubber hydrocarbon is 92 ~ 96% in natural rubber.
8. a kind of medical haemostatic material of quick injection film forming according to claim 1, which is characterized in that the system of the B liquid
It is for process：23 parts by weight lactic acid, 11 parts by weight alginic acids are added in 66 parts by weight of polypropylene yogurt liquid, ultrasonic disperse is equal
It is even, B liquid is made.
9. according to a kind of medical haemostatic material of quick injection film forming of claim 1 or 8, which is characterized in that described poly- third
The solid content of olefin(e) acid lotion is 35 ~ 40%, and pH value is 6 ~ 7.
10. a kind of application process of the medical haemostatic material of quick injection film forming according to claim 1, which is characterized in that
The specific method is as follows：
53 ~ 58 parts by weight A liquid, 42 ~ 47 parts by weight B liquid are respectively charged into two independent spaces of same container bottle setting, are made
Used time is sprayed using pressing, and A liquid, B liquid are ejected in wound simultaneously to be mixed, and nature rubber latex is rapidly solidificated into after meeting lactic acid
Film collectively constitutes the haemostatic membrane with strong adherence hemostasis by compression, silica airsetting therein with polyacrylate emulsion film forming
The blood that glue, chitosan microball, graphene quick adsorption flow out reaches fast short stopping to make haemostatic membrane be fitted closely with wound
Blood.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810384388.8A CN108310450A (en) | 2018-04-26 | 2018-04-26 | A kind of the medical haemostatic material and application process of quick injection film forming |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810384388.8A CN108310450A (en) | 2018-04-26 | 2018-04-26 | A kind of the medical haemostatic material and application process of quick injection film forming |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108310450A true CN108310450A (en) | 2018-07-24 |
Family
ID=62896137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810384388.8A Withdrawn CN108310450A (en) | 2018-04-26 | 2018-04-26 | A kind of the medical haemostatic material and application process of quick injection film forming |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108310450A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110284332A (en) * | 2019-07-29 | 2019-09-27 | 苏州经贸职业技术学院 | A kind of real silk crease-proof antibacterial finish agent and preparation method thereof |
| WO2020154822A1 (en) * | 2019-01-31 | 2020-08-06 | Universidad De Concepcion | Aerogel based on graphene oxide and chitosan with haemostatic application |
| CN113616842A (en) * | 2021-09-02 | 2021-11-09 | 中国人民解放军总医院京北医疗区 | Preparation method of hemostatic material for trauma emergency treatment |
| CN115737898A (en) * | 2022-11-21 | 2023-03-07 | 江南大学 | Hydrophobic nano-silica aerogel hemostatic material and preparation method thereof |
-
2018
- 2018-04-26 CN CN201810384388.8A patent/CN108310450A/en not_active Withdrawn
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020154822A1 (en) * | 2019-01-31 | 2020-08-06 | Universidad De Concepcion | Aerogel based on graphene oxide and chitosan with haemostatic application |
| CN110284332A (en) * | 2019-07-29 | 2019-09-27 | 苏州经贸职业技术学院 | A kind of real silk crease-proof antibacterial finish agent and preparation method thereof |
| CN113616842A (en) * | 2021-09-02 | 2021-11-09 | 中国人民解放军总医院京北医疗区 | Preparation method of hemostatic material for trauma emergency treatment |
| CN115737898A (en) * | 2022-11-21 | 2023-03-07 | 江南大学 | Hydrophobic nano-silica aerogel hemostatic material and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10179145B2 (en) | Advanced functional biocompatible polymeric matrix used as a hemostatic agent and system for damaged tissues and cells | |
| Zhang et al. | A bioinspired hemostatic powder derived from the skin secretion of Andrias davidianus for rapid hemostasis and intraoral wound healing | |
| JP6868314B2 (en) | Wound dressing containing hyaluronic acid-calcium and polylysine and its manufacturing method | |
| JP5627463B2 (en) | Adsorbent-containing hemostatic device | |
| RU2759898C2 (en) | Superabsorbent polymer hydrogel xerogel sponge, method for production and application thereof | |
| US10034958B2 (en) | Nanocomposite hydrogels | |
| US9950091B2 (en) | Composition and method for stopping hemorrhage, infection, and accelerating healing in various types of wound or burns | |
| Mecwan et al. | Recent advances in biopolymer-based hemostatic materials | |
| WO2009076873A1 (en) | A biocompatible denatured starch sponge material | |
| CN108310450A (en) | A kind of the medical haemostatic material and application process of quick injection film forming | |
| CN104189941B (en) | A kind of chitosan gel rubber hemostatic material and preparation method thereof | |
| WO2012123728A2 (en) | Haemostatic material | |
| CN102008742B (en) | Haemostatic and wound dressing containing same | |
| WO2011084326A2 (en) | Hemostatic agents and wound dressings | |
| CN109568643A (en) | A kind of preparation method and applications of the antibacterial anti hemorrhagic microballoon containing jamaicin | |
| CN112300418B (en) | Adhesive high-efficiency hemostatic microsphere and preparation method thereof | |
| CN107496973B (en) | Chitosan sponge pad band-aid capable of rapidly stopping bleeding and preparation method thereof | |
| CN111450306B (en) | External nano hydroxyapatite/polydopamine wet adhesion type styptic powder and preparation method thereof | |
| CN106902383B (en) | A kind of modified dextran-modified nanogel hemostatic material and its preparation and application | |
| CN107412843A (en) | A starch-based microporous hemostatic material with antibacterial properties and its preparation method and application | |
| CN113144280B (en) | Intelligent antibacterial hydrogel and application thereof | |
| CN108379646A (en) | A kind of bionical cloth of hemostasis | |
| CN114887111B (en) | Bioabsorbable composite hemostatic material and preparation method and application thereof | |
| CN108619556B (en) | A kind of preparation method of porous fiber composite hemostatic material | |
| CN108261560A (en) | A kind of degradable absorption hemostatic material of grain containing modified starch nano and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180724 |
|
| WW01 | Invention patent application withdrawn after publication |